The 36-month CORE-VNS study findings showed sustained seizure reduction, improved quality of life, and reduced seizure-related hospitalizations among people with drug-resistant epilepsy receiving vagus nerve stimulation therapy.
Commentary|Podcasts|October 30, 2026
Episode 178: Evolving Approaches to Epilepsy Clinical Trial Design
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with M. Scott Perry, MD. [LISTEN TIME: 15 minutes]
Advertisement
Episode 178 of the NeurologyLive®
The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.
In episode 178, “Evolving Approaches to Epilepsy Clinical Trial Design,”
During the conversation, Perry also described electroencephalography (EEG) measures as an emerging exploratory biomarker and sees potential for genetic, serum, and imaging markers to help identify patients most likely to benefit from treatment. Looking ahead, Perry noted that he envisions more targeted trials that may be smaller and shorter, with less reliance on placebo as researchers better understand disease biology and natural history.
The stories featured in this week’s Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis FDA Grants Fast Track to AV-1959R for Alzheimer Prevention FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia
EPISODE BREAKDOWN
- 1:10 - Evolution of epilepsy trial design
- 3:44 - Outcomes beyond seizure frequency
- 5:38 - Biomarkers in current trials
- 6:17 - Neurology News Minute
- 8:48 - Biomarkers and epilepsy heterogeneity
- 10:35 - Genetic screening in epilepsy trials
- 12:38 - Vision for future clinical trials
Hoping to listen on your favorite podcast app? See below:
Advertisement
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
Newly presented post hoc analyses examined diazepam nasal spray for status epilepticus in seizure clusters and intervals between clusters in children, alongside real-world data on rescue medication prescribing.
A retrospective 10-center U.S. study found stiripentol reduced convulsive seizure frequency, status epilepticus episodes, and emergency health care use in patients with Dravet syndrome.
A phase 1b/2 trial is testing an intrathecal antisense oligonucleotide designed to lower KCNT1 expression in children with a severe, drug-resistant epilepsy syndrome.
Here's some of what is coming soon to NeurologyLive® this week.
Sara Cuccurullo, MD, FAAPMR, and Talya Fleming, MD, FAAPMR, of Hackensack Meridian JFK Johnson Rehabilitation Institute, discuss the updated adult stroke rehabilitation and recovery guidelines and their implications for clinical practice.
Shadi Yaghi, MD, FAHA, Chair of Neurology at Hackensack Meridian Neuroscience Institute at Jersey Shore University Medical Center, discusses a new calculator that predicts stroke risk within 30 days of a procedure.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Incorporating the Updated AAN/AHS Migraine Prevention Guideline Into Practice
2
World Stroke Day 2026: Closing the Gap Between Stroke Onset and the Emergency Call Number
3
Blood-Based Biomarkers for Monitoring Treatment Response in Multiple Sclerosis
4
Machine Learning Spots Early Signs of MS and NMOSD Years in Advance
5